1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32215
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLam, Lyn Ley-
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorShitara, Kohei-
dc.contributor.authorSjoquist, Katrin M-
dc.contributor.authorMartin, Andrew J-
dc.contributor.authorYip, Sonia-
dc.contributor.authorKang, Yoon-Koo-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorChen, Li-Tzong-
dc.contributor.authorMoehler, Markus-
dc.contributor.authorBekaii-Saab, Tanios-
dc.contributor.authorAlcindor, Thierry-
dc.contributor.authorO'Callaghan, Christopher J-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorHague, Wendy-
dc.contributor.authorChan, Howard-
dc.contributor.authorRha, Sun Young-
dc.contributor.authorLee, Keun-Wook-
dc.contributor.authorGebski, Val-
dc.contributor.authorJaworski, Anthony-
dc.contributor.authorZalcberg, John-
dc.contributor.authorPrice, Timothy-
dc.contributor.authorSimes, John-
dc.contributor.authorGoldstein, David-
dc.date2023-
dc.date.accessioned2023-03-01T03:55:58Z-
dc.date.available2023-03-01T03:55:58Z-
dc.date.issued2023-02-22-
dc.identifier.citationBMC cancer 2023; 23(1)en_US
dc.identifier.issn1471-2407-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32215-
dc.description.abstractAdvanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeting angiogenic, stromal, and oncogenic receptor tyrosine kinases. Regorafenib 160 mg daily prolonged progression free survival compared to placebo (INTEGRATE, phase 2). Regorafenib 80 mg daily in combination with nivolumab 3 mg/kg showed promising objective response rates (REGONIVO).en_US
dc.language.isoeng-
dc.subjectAdvanced gastro-oesophageal canceren_US
dc.subjectClinical trialen_US
dc.subjectNivolumaben_US
dc.subjectRegorafeniben_US
dc.subjectTyrosine kinase inhibitoren_US
dc.titleINTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC canceren_US
dc.identifier.affiliationNHMRC Clinical Trials Centre, University of Sydney, Camperdown, Sydney, Australia. integrateii.study@sydney.edu.au.en_US
dc.identifier.affiliationRoyal North Shore Hospital, Sydney, Australia.en_US
dc.identifier.affiliationNational Cancer Centre Hospital East, Chiba, Japan.en_US
dc.identifier.affiliationNHMRC Clinical Trials Centre, University of Sydney, Camperdown, Sydney, Australia.en_US
dc.identifier.affiliationAsan Medical Centre, Seoul, South Korea.en_US
dc.identifier.affiliationSeoul National University College of Medicine, Seoul, South Korea.en_US
dc.identifier.affiliationCollege of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.en_US
dc.identifier.affiliationUniversity Medical Centre Mainz, Mainz, Germany.en_US
dc.identifier.affiliationMayo Clinic Comprehensive Cancer Centre, Phoenix, USA.en_US
dc.identifier.affiliationMcGill University Health Centre, Montreal, Canada.en_US
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen_US
dc.identifier.affiliationNHMRC Clinical Trials Centre, University of Sydney, Camperdown, Sydney, Australia.en_US
dc.identifier.affiliationCalvary Mater Newcastle, Waratah, Australia.en_US
dc.identifier.affiliationYonsei Cancer Centre, Yonsei University Health System, Seoul, South Korea.en_US
dc.identifier.affiliationSeoul National University College of Medicine, Seoul, South Korea.en_US
dc.identifier.affiliationMonash University Melbourne, Melbourne, Australia.en_US
dc.identifier.affiliationThe Queen Elizabeth Hospital, Adelaide, Australia.en_US
dc.identifier.affiliationPrince of Wales Hospital, Sydney, Australia.en_US
dc.identifier.doi10.1186/s12885-023-10642-7en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36814222-
dc.description.volume23-
dc.description.issue1-
dc.description.startpage180-
dc.subject.meshtermssecondaryNivolumab/therapeutic use-
dc.subject.meshtermssecondaryPyridines/therapeutic use-
dc.subject.meshtermssecondaryStomach Neoplasms/drug therapy-
dc.subject.meshtermssecondaryEsophageal Neoplasms/drug therapy-
local.name.researcherO'Callaghan, Christopher J
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

50
checked on Aug 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.